Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 16% Improvement Relative Risk HCQ for COVID-19  Roig et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 79 patients in Spain No significant difference in mortality Roig et al., Revista Espanola de Quimi.., Jan 2021 Favors HCQ Favors control

Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients

Roig et al., Revista Espanola de Quimioterapia, doi:10.37201/req/130.2020
Jan 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 79 hospitalized nonagenarian patients showing unadjusted HCQ mortality RR 0.84, p = 0.76.
Although the 16% lower mortality is not statistically significant, it is consistent with the significant 25% lower mortality [20‑29%] from meta analysis of the 247 mortality results to date.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 15.6% lower, RR 0.84, p = 0.76, treatment 33 of 67 (49.3%), control 7 of 12 (58.3%), NNT 11.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Roig et al., 31 Jan 2021, retrospective, Spain, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients
Sara Ortonobes Roig, Nuria Soler-Blanco, Isabel Torrente Jiménez, Eva Van Den Eynde Otero, Marc Moreno-Ariño, Mònica Gómez-Valent
Revista Española de Quimioterapia, doi:10.37201/req/130.2020
Introduction. Despite the impact of SARS-CoV-2 infection in geriatrics, data on nonagenarian patients is scarce. The aim of this study is to describe the clinical features of COVID-19-diagnosed nonagenarians, as well as its clinical evolution and therapeutic response. Material and methods. Retrospective observational study of nonagenarians, admitted for COVID-19. Sociodemographic and clinical variables were registered, including previous polypharmacy. Blood analysis data and COVID-19-specific treatment were registered. Results. A total of 79 patients were included, with 50.6% (40 patients) of mortality. None of the comorbidities registered correlated with mortality, which was significantly higher among patients with moderate/complete functional dependence, compared to those mild-dependents/independents (59.5% vs 40.5%; p=0.015). Most prescribed drugs were hydroxychloroquine/chloroquine and azithromycin. Non-survivors presented higher counts of leukocytes and neutrophils, and higher lymphopenia. Conclusions. Nonagenarians with functional dependence presented higher mortality, irrespective of comorbidities or treatment received. Implementing an integral geriatric evaluation would enhance the implementation of personalized therapeutic strategies for nonagenarians.
Aw, Woodrow, Ogliari, Harwood, Association of frailty with mortality in older inpatients with Covid-19: a cohort study, Age Ageing, doi:10.1093/ageing/afaa184
Berenguer, Ryan, Rodríguez-Baño, Jarrín, Carratalà et al., Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.07.024
Casas-Rojo, Santos, Millán-Núñez-Cortés, Lumbreras-Bermejo, Ramos-Rincón Jm et al., Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 registry, Rev Clin Esp, doi:10.1016/j.rce.2020.07.003
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, doi:10.1016/S0140-6736(20)30211-7
Cockcroft-Gault, None, ml/min
Godaert, Proye, Demoustier-Tampere, Coulibaly, Hequet et al., Clinical characteristics of older patients: the experience of a geriatric short-stay unit dedicated to patients with COVID-19 in France, J Infect, doi:10.1016/j.jinf.2020.04.009
Gómez-Belda, Fernández-Garcés, Sanchis, Madrazo, Carmona et al., COVID-19 in older adults: What are the differences with younger patients?, Geriatr Gerontol Int, doi:10.1111/ggi.14102
Huang, Hong, Shen, Huang, Zhao, China's oldest coronavirus survivors, J Am Geriatr Soc, doi:10.1111/jgs.16462
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Lian, Hao, Cai, Zhang, Zheng, Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside Wuhan, Clin Infect Dis, doi:10.1093/cid/ciaa242
Lithander, Neumann, Tenison, Lloyd, Welsh et al., COVID-19 in older people: a rapid clinical review, Age Ageing, doi:10.1093/ageing/afaa093
Liu, Chen, Lin, Han, Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients, J Infect, doi:10.1016/j.jinf.2020.03.005
Niu, Tian, Lou, Kang, Zhang et al., Clinical characteristics of older patients infected with COVID-19: a descriptive study, Arch Gerontol Geriatr, doi:10.1016/j.archger.2020.104058
Proteína, Reactiva, None
Rodríguez, Muñoz, Muela, García-Prendes, Rivera et al., Variables asociadas con mortalidad en una población de pacientes mayores de 80 años y con algún grado de dependencia funcional, hospitalizados por COVID-19 en un servicio de geriatría, Rev Esp Geriatr Gerontol, doi:10.1016/j.regg.2020.07.002
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus diseases 2019, JAMA, doi:10.1001/jama.2020.6019
Sérica, None, ng/mL)
Yan, Zhang, Gonçalves, Xiao, Wang et al., A machine learning-based model for survival prediction in patients with severe COVID-19 infection, Medrxiv, doi:10.1101/2020.02.27.20028027
Zhang, Yu, Pan, Jiang, ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis, Pharmacol Res, doi:10.1016/j.phrs.2020.104927
Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Eng J Med, doi:10.1056/NEJMoa2001017
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop